Advertisement

Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial

Published:September 03, 2022DOI:https://doi.org/10.1016/j.ejca.2022.07.028

      Highlights

      • CORALLEEN trial included patients with luminal B early breast cancer.
      • Patients received neoadjuvant ribociclib plus letrozole (R + L) or chemotherapy.
      • Health-related quality of life (HRQoL) was better in the R + L arm.
      • R + L was associated with better global health status in comparison with chemotherapy.
      • R + L also presents better results in symptom and fatigue scales.

      Abstract

      Introduction

      In the phase II CORALLEEN trial, patients with PAM50 luminal B early breast cancer (EBC) were randomised to neoadjuvant ribociclib plus letrozole (R + L) or chemotherapy based on anthracyclines and taxanes. Results from the primary efficacy analysis showed a similar proportion of patients with response at surgery in both groups. How health-related quality of life (HRQoL) outcomes with R + L compare with chemotherapy in EBC setting is still unknown. Here, we report the results of the HRQoL analysis from the CORALLEEN study.

      Methods

      A total of 106 women were randomised 1:1 to receive neoadjuvant R + L (n = 52) or chemotherapy (n = 54). Patient-reported outcomes were assessed using two questionnaires: EORTC QLQ-C30 and EORTC QLQ-BR23. Change from baseline in the global health status, functional, and symptom scales was analysed using linear mixed-effect models, and between-treatment differences were estimated along with 95% confidence interval (95% CI).

      Results

      At baseline, the overall questionnaire available rate was 94.3%, and patient-reported outcomes were similar between treatment groups. At the end of the study treatment (24 weeks), patients receiving R + L showed better global health status scores with a between-treatment difference of 17.7 points (95% CI 9.2–26.2; p-value <0.001). The R + L group also presented numerically better outcomes in all functional and symptom scales. The larger between-treatment differences in symptom severity were found in fatigue (−28.9; 95% CI −38.5 to −19.3), appetite loss (−23; 95% CI −34.9 to −11.2) and systematic therapy side-effects (−11.4; 95% CI −18.3 to −4.6).

      Conclusions

      Neoadjuvant R + L was associated with better HRQoL outcomes compared with chemotherapy in patients with luminal B EBC.

      Registration identification

      ClinicalTrials.gov Identifier: NCT03248427.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Finn R.S.
        • Crown J.P.
        • Lang I.
        • et al.
        The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
        Lancet Oncol. 2015; 16: 25-35https://doi.org/10.1016/S1470-2045(14)71159-3
        • Finn R.S.
        • Martin M.
        • Rugo H.S.
        • et al.
        Palbociclib and letrozole in advanced breast cancer.
        N Engl J Med. 2016; 375: 1925-1936https://doi.org/10.1056/nejmoa1607303
        • Cristofanilli M.
        • Turner N.C.
        • Bondarenko I.
        • et al.
        Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
        Lancet Oncol. 2016; 17: 425-439https://doi.org/10.1016/S1470-2045(15)00613-0
        • Hortobagyi G.N.
        • Stemmer S.M.
        • Burris H.A.
        • et al.
        Ribociclib as first-line therapy for HR-positive, advanced breast cancer.
        N Engl J Med. 2016; 375: 1738-1748https://doi.org/10.1056/nejmoa1609709
        • Sledge G.W.
        • Toi M.
        • Neven P.
        • et al.
        MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy.
        J Clin Oncol. 2017; 35: 2875-2884https://doi.org/10.1200/JCO.2017.73.7585
        • Goetz M.P.
        • Toi M.
        • Campone M.
        • et al.
        MONARCH 3: abemaciclib as initial therapy for advanced breast cancer.
        J Clin Oncol. 2017; 35: 3638-3646https://doi.org/10.1200/JCO.2017.75.6155
        • Tripathy D.
        • Im S.A.
        • Colleoni M.
        • et al.
        Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
        Lancet Oncol. 2018; 19: 904-915https://doi.org/10.1016/S1470-2045(18)30292-4
        • Turner N.C.
        • Slamon D.J.
        • Ro J.
        • et al.
        Overall survival with palbociclib and fulvestrant in advanced breast cancer.
        N Engl J Med. 2018; 379: 1926-1936https://doi.org/10.1056/nejmoa1810527
        • Im S.-A.
        • Lu Y.-S.
        • Bardia A.
        • et al.
        Overall survival with ribociclib plus endocrine therapy in breast cancer.
        N Engl J Med. 2019; 381: 307-316https://doi.org/10.1056/nejmoa1903765
        • Sledge G.W.
        • Toi M.
        • Neven P.
        • et al.
        The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy - MONARCH 2: a randomized clinical trial.
        JAMA Oncol. 2020; 6: 116-124https://doi.org/10.1001/jamaoncol.2019.4782
        • Slamon D.J.
        • Neven P.
        • Chia S.
        • et al.
        Overall survival with ribociclib plus fulvestrant in advanced breast cancer.
        N Engl J Med. 2020; 382: 514-524https://doi.org/10.1056/nejmoa1911149
        • Giuliano M.
        • Schettini F.
        • Rognoni C.
        • et al.
        Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
        Lancet Oncol. 2019; 20: 1360-1369https://doi.org/10.1016/S1470-2045(19)30420-6
        • Schettini F.
        • Giudici F.
        • Giuliano M.
        • et al.
        Overall survival of CDK4/6-inhibitor-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis.
        J Natl Cancer Inst. 2020; 112: 1089-1097https://doi.org/10.1093/jnci/djaa071
        • Prat A.
        • Saura C.
        • Pascual T.
        • et al.
        Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
        Lancet Oncol. 2020; 21: 33-43https://doi.org/10.1016/S1470-2045(19)30786-7
        • Cottu P.
        • D'Hondt V.
        • Dureau S.
        • et al.
        Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.
        Ann Oncol. 2018; 29: 2334-2340https://doi.org/10.1093/annonc/mdy448
        • Hurvitz S.A.
        • Martin M.
        • Press M.F.
        • et al.
        Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in Neomonarch, phase II neoadjuvant study in HR+/HER2- Breast cancer.
        Clin Cancer Res. 2020; 26: 566-580https://doi.org/10.1158/1078-0432.CCR-19-1425
        • Mayer E.L.
        • Dueck A.C.
        • Martin M.
        • et al.
        Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
        Lancet Oncol. 2021; 22: 212-222https://doi.org/10.1016/S1470-2045(20)30642-2
        • Johnston S.R.D.
        • Harbeck N.
        • Hegg R.
        • et al.
        Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE).
        J Clin Oncol. 2020; 38: 3987-3998https://doi.org/10.1200/JCO.20.02514
        • Loibl S.
        • Marmé F.
        • Martin M.
        • et al.
        Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the penelope-B trial.
        J Clin Oncol. 2021; 39: 1518-1530https://doi.org/10.1200/JCO.20.03639
        • Cardoso F.
        • Senkus E.
        • Costa A.
        • et al.
        4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4).
        Ann Oncol. 2018; 29: 1634-1657https://doi.org/10.1093/annonc/mdy192
      1. Administration D: Core Patient-Reported Outcomes in Cancer Clinical Trials Guidance for Industry DRAFT GUIDANCE.
        ([Internet] [cited 2021 Aug 4]. Available from:)
        • Aaronson N.K.
        • Ahmedzai S.
        • Bergman B.
        • et al.
        The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
        J Natl Cancer Inst. 1993; 85: 365-376https://doi.org/10.1093/jnci/85.5.365
        • Sprangers M.A.
        • Groenvold M.
        • Arraras J.I.
        • et al.
        The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study.
        J Clin Oncol. 1996; 14: 2756-2768https://doi.org/10.1200/JCO.1996.14.10.2756
        • Fayers P.
        • Aaronson N.
        • Bjordal K.
        • et al.
        EORTC QLQ-C30 scoring manual The EORTC QLQ-C30 Introduction.
        EORTC QLQ-C30 Scoring Man. vol. 30. 2001: 1-67
        • David O.
        • George R.
        • James M.
        • Benny Z.
        • Joseph P.
        Interpreting the significance of changes in health-related quality-of-life scores.
        J Clin Oncol. 1998; 16: 139-144
        • Musoro J.Z.
        • Coens C.
        • Fiteni F.
        • et al.
        Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer.
        JNCI Cancer Spectr. 2019; 3: 1-7https://doi.org/10.1093/jncics/pkz037
        • Calvert M.
        • Blazeby J.
        • Altman D.G.
        • et al.
        Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension.
        JAMA. 2013; 309 (PMID: 23443445): 814-822
        • Coens C.
        • Pe M.
        • Dueck A.C.
        • et al.
        International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.
        Lancet Oncol. 2020; 21: e83-e96https://doi.org/10.1016/S1470-2045(19)30790-9
        • Najera-Zuloaga J.
        • Lee D.J.
        • Arostegui I.
        A beta-binomial mixed-effects model approach for analysing longitudinal discrete and bounded outcomes.
        Biom J. 2019; 61: 600-615https://doi.org/10.1002/bimj.201700251
        • Martín M.
        • Zielinski C.
        • Ruiz-Borrego M.
        • et al.
        Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
        Eur J Cancer. 2022; 168: 12-24https://doi.org/10.1016/j.ejca.2022.03.006
        • Park Y.H.
        • Kim T.Y.
        • Kim G.M.
        • et al.
        Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
        Lancet Oncol. 2019; 20: 1750-1759https://doi.org/10.1016/S1470-2045(19)30565-0
        • Kahan Z.
        • Gil-Gil M.
        • Ruiz-Borrego M.
        • et al.
        Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: patient-reported outcomes in the PEARL study.
        Eur J Cancer. 2021; 156: 70-82https://doi.org/10.1016/j.ejca.2021.07.004
        • Lee S.
        • Im S.A.
        • Kim G.M.
        • et al.
        Patient-reported outcomes of palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer: a prospective, open-label, randomized phase ll trial (KCSG-BR 15-10).
        Cancers (Basel). 2020; 12: 1-12https://doi.org/10.3390/cancers12113265
        • Verma S.
        • O'Shaughnessy J.
        • Burris H.A.
        • et al.
        Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
        Breast Cancer Res Treat. 2018; 170: 535-545https://doi.org/10.1007/s10549-018-4769-z
        • Fasching P.A.
        • Beck J.T.
        • Chan A.
        • et al.
        Ribociclib plus fulvestrant for advanced breast cancer: health-related quality-of-life analyses from the MONALEESA-3 study.
        Breast. 2020; 54: 148-154https://doi.org/10.1016/j.breast.2020.09.008
        • Harbeck N.
        • Franke F.
        • Villanueva-Vazquez R.
        • et al.
        Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7).
        Ther Adv Med Oncol. 2020; 12
        • Harbeck N.
        • Rastogi P.
        • Martin M.
        • et al.
        Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
        Ann Oncol. 2021; 32: 1571-1581https://doi.org/10.1016/j.annonc.2021.09.015
        • Rugo H.S.
        • O'Shaughnessy J.
        • Jhaveri K.L.
        • et al.
        Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC).
        J Clin Oncol. 2022; 40: 1015
        • Rugo H.S.
        • O'Shaughnessy J.
        • Boyle F.
        • et al.
        Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
        Ann Oncol. 2022; 33https://doi.org/10.1016/j.annonc.2022.03.006
        • Ades F.
        • Zardavas D.
        • Bozovic-Spasojevic I.
        • et al.
        Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.
        J Clin Oncol. 2014; 32: 2794-2803https://doi.org/10.1200/JCO.2013.54.1870